BMO Capital Positive on Abbvie (ABBV) Humira Win Versus Amgen (AMGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
AbbVie (ABBV) Taps Session High
January 15, 2016 10:32 AM ESTAbbVie (NYSE: ABBV) advanced to session highs Friday morning, rising 3.3%.
Amgen (AMGN) Rejected in Challenges to Abbvie (ABBV) Patents on Humira - Bloomberg
January 14, 2016 3:58 PM ESTAmgen (NASDAQ: AMGN) Rejected in Challenges to Abbvie (NYSE: ABBV) Patents on Humira - Bloomberg
... MoreUPDATE: AbbVie (ABBV) Pops on Amgen-Related IPR Patent Chatter
January 14, 2016 3:43 PM EST(Updated - January 14, 2016 3:49 PM EST)
AbbVie (NYSE: ABBV) pops to session highs.
UPDATE - AbbVie is said to be gaining on denial of Amgen's (Nasdaq: AMGN) IPR patent reexaminations covering the '157 and '158 patents, according to market chatter.
Shares of AbbVie rose as much as 11 percent on Thursday's session.
... More